The Food and Drugs Authority (FDA) has alerted the general public especially hospitals, clinics and pharmacies of an unregistered antibiotic, Ciprobiotic 250 imported and being distributed on the Ghanaian market by Kojach Limited.
The product, Ciprobiotic 250 (Ciprofloxacin Oral Suspension 250mg/5ml), according to FDA has not undergone the necessary evaluations by the FDA; hence, the Authority cannot guarantee its quality, safety and efficacy.
It explained that information on the packaging of the product indicated that it was manufactured in India by Fredun Pharmaceuticals Limited for Kojach Limited, who is indicated as the brand name holder.
The FDA has therefore warned health facilities and the general public to desist from stocking and dispensing the unregistered antibiotic Hospitals, clinics and “pharmacies having stocks of Ciprobiotic 250 (Ciprofloxacin oral suspension 250mg/5ml) are advised to immediately hand them over to any of the FDA offices nationwide”.
Ciprofloxacin is an antibiotic used to treat different types of bacterial infections including Skin infections, Urinary tract infections, Gonorrhea and Typhoid fever.
The FDA once again will like to assure the general public of its resolve to protect public health and safety. You may contact the FDA on the following contact numbers; 020 8204968 and 024 4337235. GNA